Loading...

Reported Sunday, Oct 11 - 7:39pm EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…

BioAge Labs is reorienting its clinical strategy toward ophthalmic indications, specifically targeting diabetic macular edema (DME) with its lead candidate, BGE-102. The pivot follows cooling interest in the cardiovascular inflammation sector after the failure of Novo Nordisk's ZEUS trial, which ser

Reported Tuesday, Sep 8 - 8:33am EDT (TheFly subscription required to read more.)

Several brokerages have updated their recommendations and price targets on shares of BioAge Labs (NASDAQ: BIOA) in the last few weeks: 8/3/2026 – BioAge Labs had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock. 7/31/2026 – BioAge Labs had its “buy” rating reaffirmed by Roth Capital. [...]

A biological age score calculated from just four routinely available measures was linked to future cognitive problems, suggesting that how the body ages may reveal risks that chronological age alone can miss. Study: Association between light BioAge and cognitive impairment risk in middle-aged and elderly people: a retrospective cohort study. Image Credit: Lightspring A recent study published in the journal Scientific Reports examined the relationship between light BioAge and the risk of cognitive impairment and cognitive decline in middle-aged and older adults, utilizing data from a large Chinese longitudinal cohort. Cognitive Impairment and Biological Aging Cognitive impairment describes a decline in mental abilities, including memory, reasoning, attention, and language, which goes beyond typical age-related changes. It is prevalent in older adults and can range from mild deficits to severe loss of independence, with dementia representing the most severe and disabling manifestation. Mild cognitive impairment affects approximately 15.6% of community-dwelling adults aged 50 years and older worldwide, while prevalence in China has been estimated at 19.6%. Its effects extend beyond cognition, impacting psychological well-being, social participation, physical function, and contributing to a substantial economic burden. Age is the primary risk factor, but others include cardiovascular diseases, hypertension, obesity, diabetes, smoking, depression,...

A study of 4,818 middle-aged and older Chinese adults found that higher light BioAge was associated with greater risks of cognitive impairment, episodic memory decline, and reduced mental intactness. ...

Using sets of biomarkers of human ageing, a ‘bioage’ score was established allowing calculation of ‘age difference’ (bioage minus chronological age). Age difference, but not chronological age, was co....

Methods to quantify biological aging are emerging as new measurement tools for epidemiology and population science and have been proposed as surrogate measures for healthy lifespan extension in gerosc...